Cue Biopharma, Inc. (CUE)

NASDAQ: CUE · IEX Real-Time Price · USD
2.23
-0.16 (-6.69%)
Sep 30, 2022 4:00 PM EDT - Market closed
-6.69%
Market Cap 78.90M
Revenue (ttm) 11.68M
Net Income (ttm) -48.84M
Shares Out 35.38M
EPS (ttm) -1.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 110,501
Open 2.35
Previous Close 2.39
Day's Range 2.20 - 2.45
52-Week Range 2.20 - 18.42
Beta 1.66
Analysts Buy
Price Target 11.90 (+433.6%)
Earnings Date Nov 7, 2022

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-1... [Read more...]

Industry Biotechnology
IPO Date Jan 2, 2018
CEO Daniel Passeri
Employees 57
Stock Exchange NASDAQ
Ticker Symbol CUE
Full Company Profile

Financial Performance

In 2021, Cue Biopharma's revenue was $14.94 million, an increase of 373.68% compared to the previous year's $3.15 million. Losses were -$44.16 million, -1.39% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CUE stock is "Buy." The 12-month stock price forecast is 11.9, which is an increase of 433.63% from the latest price.

Price Target
$11.9
(433.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why Cue Biopharma, Inc. (CUE) Looks Ripe for Bottom Fishing

Cue Biopharma, Inc. (CUE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement amo...

1 month ago - Zacks Investment Research

Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulat...

1 month ago - GlobeNewsWire

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulat...

2 months ago - GlobeNewsWire

Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulat...

4 months ago - GlobeNewsWire

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate...

4 months ago - GlobeNewsWire

Cue Biopharma Reports First Quarter 2022 Financial Results

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate...

4 months ago - GlobeNewsWire

Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 6.4% Jump Turn into More Strength?

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow...

5 months ago - Zacks Investment Research

Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...

7 months ago - Zacks Investment Research

Cue Biopharma, Inc. (CUE) Soars 8.3%: Is Further Upside Left in the Stock?

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ...

8 months ago - Zacks Investment Research

Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion o...

CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

8 months ago - GlobeNewsWire

Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

8 months ago - GlobeNewsWire

Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

9 months ago - GlobeNewsWire

Cue Biopharma to Present at the Piper Sandler 33rd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

10 months ago - GlobeNewsWire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

10 months ago - GlobeNewsWire

Analysts Estimate Cue Biopharma, Inc. (CUE) to Report a Decline in Earnings: What to Look Out for

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for t...

Research demonstrates Immuno-STAT™ Biologics lead to direct and selective activation and expansion of anti-viral cytotoxic T cells in vivo specific for human immunodeficiency virus (HIV) and cytomegalov...

11 months ago - GlobeNewsWire

Cue Biopharma Announces Publication in Nature Journal, Scientific Reports, of Immunotherapeutic Platforms Immuno-STAT...

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage...

1 year ago - GlobeNewsWire

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio

1 year ago - GlobeNewsWire

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansi...

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage ...

1 year ago - GlobeNewsWire

Cue Biopharma to Host Business Update Call and Webcast

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 year ago - GlobeNewsWire

Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 year ago - GlobeNewsWire

Earnings Preview: Cue Biopharma, Inc. (CUE) Q2 Earnings Expected to Decline

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 year ago - GlobeNewsWire

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ ...

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 year ago - GlobeNewsWire

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectivel...

1 year ago - GlobeNewsWire